Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). (4th September 2015)

• Record Type: Journal Article
• Authors: Zhang, Xiaoyan; Hamadeh, Issam S; Song, Shuang; Katz, Joseph; Moreb, Jan S; Langaee, Taimour Y; Lesko, Lawrence J; Gong, Yan
• Is Part Of: Journal of bone and mineral research. Volume 31:Number 2(2016:Feb.)
• Page Start: 336
• Page End: 340
• Publication Date: 2015-09-04
• Subjects: OSTEONECROSIS OF THE JAW -- FAERS -- BISPHOSPHONATES -- RANKL INHIBITORS -- ANTIANGIOGENIC AGENTS; Bones -- Metabolism -- Periodicals; Mineral metabolism -- Periodicals; 612.392
• DOI: 10.1002/jbmr.2693
• Languages: English
• ISSNs: 0884-0431

Abstract

ABSTRACT: Osteonecrosis of the jaw (ONJ) is a serious adverse drug event that was initially reported with intravenous bisphosphonates (BPs) and more recently with other classes of drugs such as receptor activator of NF‐κB ligand (RANKL) inhibitor, antiangiogenic agents, and mammalian target of rapamycin (m‐TOR) inhibitors. The purpose of this study is to analyze the ONJ cases and the associated drugs in the US Food and Drug Administration's adverse event reporting system (FAERS). The FAERS database was queried for the adverse drug events reported from the first quarter of 2010 to the first quarter of 2014. The reporting odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each queried drug. A total of 17, 119 unique ONJ cases were identified. In the overall analysis, the drugs with the highest reporting ORs were BPs: pamidronate (OR = 498.9), zoledronate (OR = 171.7), and alendronate (OR = 63.6), whereas denosumab had lower ORs than all the BPs except for etidronate. The antiangiogenic and m‐TOR inhibitors had the lowest ORs. In cancer patients who were treated for prevention of skeletal‐related events (SREs), the reporting ORs for zoledronate and denosumab were 125.2 and 4.9, respectively. In patients with osteoporosis, the ORs were 1.1 (1.0–1.18) for zoledronate and 0.63 (0.56–0.70) for denosumab, respectively. Our analysis of the FAERS database showed that the intravenous BPs were associated with the highest risk for ONJ, RANKL inhibitor was associated with risk comparable to BPs used for osteoporosis such as etidronate, and the antiangiogenic agents and m‐TOR inhibitors were associated with the lowest risk for ONJ. The high risk for ONJ with zoledronate and denosumab was mainly observed in those who were treated for prevention of SREs, whereas there was limited evidence for such risk in those who were treated for osteoporosis. © 2015 American Society for Bone and Mineral Research.